ClinicalTrials.gg
RecruitingNCT06954480DIAMONDUpdated May 22, 2026

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

A Phase 2 interventional study of Datopotamab Deruxtecan (Dato-DXd) and Durvalumab in Triple Negative Breast Cancer, sponsored by Queen Mary University of London. Recruiting at 2 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Queen Mary University of London · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing durvalumab in Triple Negative Breast Neoplasms — 4 open to participants now, 5 under way, none of them phase 3. durvalumab · Triple Negative Breast Neoplasms.

Planned enrollment
3rd of 12
140 · median 48
Started
2025
the only one that year
Phase 2
7 of 12
3 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Queen Mary University of London

Among the 12 studies testing durvalumab in Triple Negative Breast Neoplasms, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 2, and was the 12th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

4 of the 12 studies testing durvalumab in Triple Negative Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing durvalumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast cancer (TNBC). Globally, breast cancer is the most common malignancy in women and the second most common cancer overall. The term TNBC is used to define tumours that do not express oestrogen receptors, progesterone receptors and HER2 receptors. TNBC comprises 10 -15% of all breast cancers. It remains the subtype with poorest outcome and there is a significant need to develop new therapies for this group of patients especially. Moreover, the PDL1-negative tumour has demonstrated no benefit from standard 1st line treatment of chemotherapy plus immune checkpoint inhibitors.

Read the detailed description

The aim of this study is to demonstrate the superiority of Datopotamab deruxtecan (Dato-DXd) plus Durvalumab (Durvalumab) relative to Dato-DXd alone in patients with PDL1-negative advanced or metastatic triple negative breast cancer (TNBC). This is also the primary endpoint of this study and effectivenss measured by progression-free survival. Dato-DXd is an antibody drug conjugate (ADC) that targets tumour-associated calcium signal transducer 2, TROP2, a transmembrane protein that is highly expressed in various epithelial tumors including breast cancer. Durvalumab is an immune checkpoint inhibitor and is expected to stimulate the patient's anti-tumour immune response by binding to PD-L1 and shifting the balance toward an anti-tumour response. The preclinical and clinical evidence have suggested synergistic activity between antibody drug conjugate and immune checkpoint inhibitor. This study will recruit 140 patients, aged 18 and over and consenting patients will be randomly placed into one of two treatment groups. One group will receive Datopotamab deruxtecan in combination with Durvalumab and the other groups will receive Datopotamab deruxtecan alone. Treatment will continue unless there is evidence of unacceptable toxicity, disease progression, or if the patient requests to stop the treatment or death. Safety and tolerability as well as progression free survival, overall survival, clinical benefit rate, duration of response and duration of clinical benefit and quality of life will be assessed.

PD-L1 is part of a complex system of receptors and ligands that are involved in controlling T-cell activation. The PD-1 receptor (cluster of differentiation [CD]279) is expressed on the surface of activated T cells. It has 2 known ligands: programmed cell death ligand-1 (PD-L1; B7-H1; CD274) and programmed cell death ligand-2 (PD-L2; B7-DC; CD273). PD-L1/PD-L2 belong to a family of immune checkpoint proteins that act as coinhibitory factors, which can halt or limit the development of T cell response. When PD-L1 binds to PD-1, an inhibitory signal is transmitted into the T cell, which reduces cytokine production and suppresses T cell proliferation. Tumour cells exploit this immune checkpoint pathway as a mechanism to evade detection and inhibit immune response.

Sites will perform local PD-L1 testing to confirm the PD-L1 status of potentially eligible patients. PD-L1 negativity in this trial will be defined as 22C3 Combined Positive Score (CPS) of less than 10.

Durvalumab is a human mAb of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not PD-L2) with PD-1 on T cells and CD80 (B7.1) on immune cells. The proposed mechanism of action for durvalumab is interference in the interaction of PD-L1 with PD-1 and CD80 (B7.1). The blockade of PD-L1/PD-1 and PD-L1/CD80 interactions releases the inhibition of immune responses, including those that may result in tumor elimination. In vitro studies demonstrate that durvalumab antagonizes the inhibitory effect of PD-L1 on primary human T cells, resulting in restored interferon-gamma (IFN-γ)-induced proliferation. In vivo studies have shown that durvalumab inhibits tumor growth in xenograft models via a T cell-dependent mechanism. Based on these data, durvalumab is expected to stimulate the patient's antitumor immune response by binding to PD-L1 and shifting the balance toward an antitumor response. Durvalumab has been engineered to reduce antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.

Dato-DXd is an antibody drug conjugate that targets tumour-associated calcium signal transducer 2, TROP2, a transmembrane protein that is highly expressed in various epithelial tumours including breast cancer. TROP2 has several binding partners, including claudin 1, claudin 7, cyclin D1, protein kinase C, phosphatidylinositol 4,5-bisphosphate, and insulin-like growth factor 1. By binding to these targets, TROP2 affects tight junctions at the epithelial barrier and increases tumour proliferation, podosome formation, and Raf and NF-kappa activation and suppresses IGF-1R signaling [21,22]. Its expression correlates with aggressive tumour behaviour and has been used as a prognostic marker in several types of cancer.

DNA topoisomerase I is an enzyme that acts by causing a transient break in 1 strand of DNA. This enables the unwinding of positive or negative supercoiled DNA through a hindered rotary system, thus allowing the separation of the double-helix strands. This activity is prominent during cell replication. Inhibition of DNA topoisomerase I can lead to cell apoptosis following multiple breaks in the cell DNA. DNA topoisomerase I has therefore been identified as a potential target for cancer treatment.

In order to overcome the challenges of delivering cytostatics specifically into cancer cells, ADCs have been developed. ADCs are composed of an antibody, a linker, and a cytotoxic agent. ADCs are payload delivery systems that can target cells that express the preferred marker. The ADC specifically binds and is internalized into the target cells, and enzymatic processes release the drug into the cytoplasm.

Dato-DXd binds to TROP2, is internalized, and undergoes enzymatic processing. Thereafter the DNA Dato-DXd binds to TROP2, and after further enzymatic processing, the DNA topoisomerase I inhibitor DXdis released, inhibits cell replication, and promotes cell apoptosis. The anti-TROP2 component, is a humanized IgG1 kappa monoclonal antibody. The released drug is a DNA topoisomerase I inhibitor derivative of exatecan. The monoclonal antibody is covalently conjugated to a drug-linker, which is composed of a cleavable maleimide tetrapeptide linker and the released drug. The tetrapeptide linker is designed to be stable in plasma to reduce systemic exposure to the released drug.

In vitro studies indicate that Dato-DXd exhibits TROP2 expression-dependent cell growth inhibitory activity, and in vivo studies using a tumor-bearing mouse model indicate that administration of Dato-DXd results in the regression of TROP2-positive tumors. The biodistribution and antitumor activity of the ADC are expected to depend on the expression level of the target antigen in tumor tissue.Dato-DXd has been evaluated in multiple solid tumors ,including NSCLC, and TNBC, HR+/HER2- BC, and urothelial cancer have high expression of TROP2, 1,2 and the DNA topoisomerase I inhibitor, irinotecan, shows clinical efficacy in these indications 9,10. Dato-DXd has shown preliminary efficacy in the ongoing clinical studies.

The screening period for the trial is 28 days. Following randomisation, patients must commence on trial treatment within 3 days.

There are specific protocol mandated pre-randomisation eligibility criteria that needs to be fulfilled, which includes the below:

  1. Assessing eligibility thoroughly using the protocol inclusion and exclusion criteria and obtaining informed consent.
  2. Conducting local PD-L1 assessment and confirming PD-L1 negativity by 22C3 Combined Positive Score (CPS) of less than 10.
  3. A representative formalin-fixed, paraffin embedded (FFPE) tumour specimen with the supporting report is required to enable the definitive diagnosis of TNBC, with adequate viable tumour cells in a tissue block.
  4. Obtaining medical history and demographics.
  5. Confirming ECOG performance status.
  6. Completing limited physical exam (including clinical breast examination), vital sins and weight with height.
  7. Haematology and Biochemistry bloods.
  8. Urinalysis.
  9. Pregnancy test.
  10. Thyroid function test.
  11. Coagulation and Virology test.
  12. Yearly ophthalmologic assessment if done as routine standard of care.
  13. CT tumour assessment (using RECIST v1.1).
  14. Brain scan.
  15. Collection of adverse events and concomitant medications.
  16. Completion of QOL questionnaires.
  17. Collection if research blood samples.

Once the above assessments have satisfactorily completed, the sponsor team, CECM DIAMOND coordinating team will check the screening eCRF data against the protocol and confirm eligibility. Once this has been completed, site staff can then proceed to randomising the patient on the Interactive Response Technology (IRT) system. Both the site and pharmacy staff and the CECM coordination team will receive a confirmation of randomisation via email.

Patients will be randomised in 1:1 rations to receive one of the two following treatment arms:

  1. Dato-DXd (Dose 6mg/kg, IV) plus Durvalumab (1120 mg, IV) on Day 1 Q3W.
  2. Dato-DXd (Dose 6mg/kg) on Day 1 Q3W.

Randomisation will be stratified as a three-part stratification by the following:

  1. Is de novo; or
  2. has treatment-free interval of \< = 12 months or
  3. has a treatment-free interval of > 12 months

Throughout the duration of the trial treatment, the below assessments will be performed (+/- 3 days) and associated data collected and reported on the eCRF:

  1. ECOG performance status.
  2. Limited physical exam (including clinical breast examination), vital sins and weight with height.
  3. Haematology and Biochemistry bloods.
  4. Pregnancy test.
  5. Thyroid function test.
  6. CT tumour assessment (using RECIST v1.1) every 9 weeks until disease progression.

6. Yearly ophthalmologic assessment if done as routine standard of care. 7. Adverse events and concomitant medications. 8. QOL questionnaires. 9. Patient review for safety occurring only on day 14 from cycle 1 to 3, where information on adverse events on concomitant medications will be collected.

During the safety visit, which occurs 90 days after the last dose (+/- 7 days), the below assessments will be performed and associated data collected and reported on the eCRF:

  1. ECOG performance status.
  2. Limited physical exam (including clinical breast examination), vital sins and weight with height.
  3. Haematology and Biochemistry bloods.
  4. Pregnancy test.
  5. Thyroid function test.
  6. Ophthalmologic assessment if done as routine standard of care.
  7. Adverse events and concomitant medications.
  8. QOL questionnaires.

Upon disease progression, the below assessments will be performed and associated data collected and reported on the eCRF:

  1. CT tumour assessment (using RECIST v1.1).
  2. Adverse events and concomitant medications.
  3. Optional fresh tumour biopsy.
  4. Research blood samples.

When a patient discontinues study treatment, they will be followed up for subsequent anti-cancer therapies, disease and survival status until death, loss to follow-up or withdrawal of consent (whichever comes first) All patients will be followed up for survival until 2 year post last patient treatment discontinuation. Each patient will be followed up at least every 6 months in the follow up period. If patient requests to be withdrawn from follow-up; this request must be documented in the source documents and signed by the investigator. If the patient withdraws from study treatment but not from follow-up, the study staff may use patient medical records to obtain information about subsequent anti-cancer therapies.

03

Conditions studied

  • Triple Negative Breast Cancer

Keywords

  • Triple Negative Breast Cancer
  • breast cancer
  • PDL1-negative
  • Datopotamab Deruxtecan
  • Durvalumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written .
  2. Ability to comply with the protocol.
  3. Female ≥ 18 years of age.
  4. Triple-negative disease, defined as tumour cells being:

    • Negative for ER with \<10% of tumour cells positive for ER on IHC or IHC score (Allred) of ≤3.
    • Negative for PR with \<10% of tumour cells positive for PR on IHC or IHC score (Allred) of ≤3 or PR unknown, and
    • Negative for with 0, 1+ or 2+ intensity on IHC and no evidence of amplification on ISH.
  5. PDL1 negative, defined as 22C3 CPS\<10.
  6. Patients must have:

    • at least one lesion, not previously irradiated, that can be measured accurately at baseline as ≥ 10mm in the longest diameter (except lymph nodes which must have short axis ≥ 15mm) with computed tomography (CT) or magnetic resonance imaging (MRI) performed within 28 days prior to randomisation which is suitable for accurate repeated measurements, or
    • lytic or mixed (lytic + sclerotic) bone lesions in the absence of as defined above; patients with sclerotic/osteoblastic bone lesions only in the absence of measurable disease are not eligible. Patient that cannot be assessed by the CT or MRI should be excluded from the study.
  7. Representative formalin-fixed paraffin embedded (FFPE) breast tumour samples with an associated pathology report from the primary or recurrent cancer that are determined to be available and sufficient for central testing OR tumour accessible for .
  8. performance status 0-1.
  9. ≥12 weeks.
  10. Adequate haematologic and end-organ function within 28 days prior to the first study treatment defined by the following:

    • ≥ 1500 cells/μL (1.5 x 109/L) (without granulocyte) colony-stimulating factor support within 2 weeks prior to Cycle 1, Day 1).
    • WBC > 2500/μL (2.5 x 109/L).
    • count ≥ 100,000/μL (100 x 109/L) (transfusion not permitted within 28 days of study medication).
    • ≥ 9.0 g/dL (90g/L) with no blood transfusions (packed red blood cells).
    • Serum albumin ≥ 3g/dL.
    • (SGOT) or ALT (SGPT) and ALP ≤ 2.5 times the institutional (ULN), ≤ 1.5 x ULN (patients with liver who have AST or ALT ≤ 5 x the institutional ULN may be enrolled).
    • ≤ 1.5 × the institutional ULN, INR \<1.5 and absence of evidence of impaired hepatic synthesis function. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
    • Serum Creatinine ≤ 1.5 x institutional ULN.
    • ≥ 40mL/min as assessed by standard methodology at the investigating center (i.e., , MDRD or CKD-EPI formulae, EDTA clearance or 24 h urine collection).
    • No evidence of haematuria: +++ on microscopy or dipstick.
  11. Patients of are eligible provided they have a negative serum or urine pregnancy test on Cycle 1, Day 1 (within 72 hours) of study treatment, preferably as close to the first dose as possible. Patients must agree to use adequate , defined as those methods with a failure rate of \< 1 % per year beginning 14 days before the first dose of study drug and for 7 months after the last dose of study drug. Also, participants must not donate, or retrieve for their own use, ova at any time during this study and for at least 7 months after the last dose of treatment. Preservation of ova should be considered prior to randomisation or the first dose of study intervention.
  12. Body Weight > 30 kg.

Exclusion criteria

Exclusion Criteria:

  1. Prior chemotherapy, immunotherapy (including durvalumab) or treatment with PARP inhibitors for advanced or breast cancer.
  2. Prior treatment with (eg atezolizumab, pembrolizumab) or DNA topoisomerase I or TROP2- or -targeting ADCs and TROP2 targeted therapy in the (neo) setting within 6 months from the end of treatment and randomisation into this study.
  3. Patients with prior allogeneic stem cell or solid organ transplantation.
  4. Patients must not have a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent), or had oral or IV steroids for 14 days prior to the first dose of study drug; the use of intranasal, inhaled corticosteroids topical steroids, or local steroid injections, physiologic replacement doses of glucocorticoids (i.e. for adrenal insufficiency) and mineralocorticoids (e.g. fludrocortisone) or steroids as premedication for reactions (e.g., CT scan premedication is allowed.
  5. Administration of a within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
  6. Active or prior documented or inflammatory disorders including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, , rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis , Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement therapy
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included
    • Patients with celiac disease controlled by diet alone
  7. History of idiopathic pulmonary fibrosis (including pneumonitis or interstitial lung disease), drug-induced pneumonitis, radiation pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia) requiring steroids, or evidence of active pneumonitis on screening chest CT scan.
  8. Active infection requiring systemic therapy.
  9. History of infection.
  10. Known active hepatitis infection (defined as having a positive surface antigen [HBsAg] test at screening) or . Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  11. Known history of active tuberculosis (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
  12. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining .
  13. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the study protocol.
  14. Concurrent treatment with other experimental drugs or participation in another clinical trial with therapeutic intent within 28 days prior to randomisation.
  15. Pregnant and lactating female patients.
  16. Major surgical procedure within 4 weeks prior to randomisation or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.
  17. other than breast cancer within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent).
  18. Severe infections within 28 days prior to randomisation in the study including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.
  19. Any unresolved toxicity Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria:

    • Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
    • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.
  20. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, situations that would limit compliance with study requirement, substantially increase risk of incurring AEs.
  21. History of .
  22. Has corneal disease.
  23. Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
  24. History of active primary immunodeficiency.
  25. Known allergy or hypersensitivity to any of the study drugs or any of the study drug .
  26. or neoplastic spinal cord compression. Patients whose brain metastases have been treated may participate provided they show radiographic stability (defined as 2 brain images, both of which are obtained after treatment to the brain metastases. These imaging scans should both be obtained at least four weeks apart and show no evidence of intracranial progression. In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have resolved or be stable either, without the use of steroids, or are stable on a steroid dose of ≤10mg/day of prednisone or its equivalent and anticonvulsants for at least 14 days prior to the start of treatment. Brain metastases will not be recorded as Target Lesions at baseline.
  27. Mean corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).
  28. Patients who have received prior anti-PD-1, anti PD-L1 or anti CTLA-4:

    • Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
    • All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.
    • Must not have experienced a ≥Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: Patients with endocrine AE of ≤Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.
    • Must not have required the use of additional other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Dato-DXd plus Durva

    In arm A, patients will receive Durvalumab 1120mg plus Dato-DXd 6.0mg/kg.

    Drug: Datopotamab Deruxtecan (Dato-DXd) · Drug: Durvalumab

  • Active comparator
    Arm B - Dato-DXd

    In arm B, patients will receive Dato-DXd 6.0mg/kg.

    Drug: Datopotamab Deruxtecan (Dato-DXd)

Interventions

  • DrugDatopotamab deruxtecanStudies of Datopotamab deruxtecanDatopotamab deruxtecan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive Dato-DXd 6.0mg/kg, which will be administered by infusion on day 1 of each 21-day cycle.

  • Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. PFS is defined as the time from the date of randomisation to the date of first documented confirmed tumour progression (using RECIST 1.1) or death from any cause, whichever occurs first in all patients.

    PFS is defined as the time from randomisation to disease progression or relapse (as assessed by the site radiologist and/or investigator, using RECIST, Version 1.1) or death on study from any cause (defined as death within 30 days of the last study treatment), whichever occurs first. For patients who have not died or experienced disease progression at the end of study, PFS will be censored on the last date the patient was known to be progression free.

    Time frame: PFS is defined as the time from the date of randomisation to date of first documented confirmed disease progression or death, which ever occurs first, assessed on average up to 12 months.

Secondary outcomes

  1. OS is defined as the time from date of randomisation to the date of death due to any cause in all patients.

    Overall survival is defined as the time from randomisation to death from any cause. All deaths will be included, whether they occur on study or following treatment discontinuation. For patients who have not died, overall survival will be censored at the date of last contact.

    Time frame: From date of randomisation to the date of death due to any cause in all patients, assessed on average up to 12 months.

  2. DoR is defined as the time from first documentation of CR or PR to confirmed disease progression using RECIST 1.1, or death on study from any cause, whichever occurs first, in patients with objective response.

    Time frame: The time from first documentation of CR or PR to confirmed disease progression, or death on study from any cause, whichever occurs first in patients with objective response, assessed on average up to 12 months.

  3. CBR is defined as the percentage of patients who have achieved at least one CR or PR or met the SD criteria at least once after randomisation for a minimum interval of 24 weeks continuously (using RECIST 1.1).

    Clinical Benefit rate is defined as number of patients with complete or partial response or stable disease maintained ≥24 weeks (as assessed by the site radiologist and/or investigator, using RECIST1.1) divided by the number of patients in the analysis. Patients without a post-baseline tumour assessment will be considered to have no clinical benefit. An estimate of the clinical benefit rate and 95% CIs (Blyth-Still-Casella; 21-22) will be calculated for each treatment arm. CIs for the difference in clinical benefit rate (Satner and Snell 1980; Berger and Boos 1994; 23-24) will be calculated. The relative risk (treatment:control) will be reported along with the associated 95% confidence interval. Statistical inference will be evaluated using Chi-square statistic; the Fisher's exact test may be used if the expected counts in some cells are small.

    Time frame: Up to 24 weeks

  4. DoCB is calculated as time (in months) from randomisation to progression or death from any cause in patients with a clinical benefit.

    For patients with an objective response, duration of objective response is defined as the time from initial complete or partial response to disease progression or death on study from any cause (defined as death within 30 days of the last study treatment), whichever occurs first. For patients with a clinical benefit (objective response or stable disease maintained ≥24 weeks), duration of clinical benefit is defined as the time from randomisation to disease progression or death on study from any cause (defined as death within 30 days of the last study treatment), whichever occurs first. Methods for handling censoring and for analysis are the same as those described for PFS.

    Time frame: From the time (in months) from randomisation to progression or death from any cause in patients with a clinical benefit, assessed on average up to 12 months..

  5. Changes in quality of life measured by the time to deterioration (TTD)

    Changes in quality of life measured by the time to deterioration (TTD) in Items 29 (overall health) and 30 (overall QoL) of the EORTC Quality of Life Questionnaire Core 30 (QLQ-C30) and the percentages of patients with a decrease or increase of ≥ 10 points on the global health status/HRQoL scale of the EORTC QLQ-C30 and on subsets, respectively. Patient reported outcome assessment is one type of clinical outcome assessment and is a general term referring to all outcomes and symptoms that are directly reported by the participant. PROs have become important in evaluating the efficacy and tolerability of study interventions in clinical studies and will aid in understanding of the benefit/risk evaluation.

    Time frame: From the time of enrollment to the safety visit (90 days +/- 7 days after the last dose.), assessed up to at least 122 PFS events have occured

  6. Incidence, nature and severity of adverse events with severity determined according to CTCAE v5.0.

    Time frame: From the time of enrollment to the safety visit (90 days +/- 7 days after the last dose.), assessed up to at least 122 PFS events have occurred

07

Study locations

1 of 2 sites recruiting
  • Barts Cancer Institute, Centre of Experimental Cancer Medicine
    London, EC1M 6BQ, United Kingdom
    Not yet recruiting
  • Barts Health NHS Trust
    London, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2028, 28 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 28 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2025
First posted
May 1, 2025
StartActual
Oct 27, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2030
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06954480
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Oct 27, 2025
Primary completion
Feb 2028 (estimated)
Completion
Feb 2030 (estimated)
Last update
May 22, 2026

Study contacts

Peter Schmid, MD PhD, FRCP
Contact
bci-diamond@qmul.ac.uk
+44(0)20 7882 8764 ext. 8764
Peter Schmid, MD PhD, FRCP
study director · Queen Mary University of London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion